| Combination of | |
|---|---|
| Dolutegravir | Integrase strand transfer inhibitor |
| Lamivudine | Nucleoside reverse transcriptase inhibitor |
| Tenofovir disoproxil | Nucleoside reverse transcriptase inhibitor |
| Clinical data | |
| Other names | Tenofovir/lamivudine/dolutegravir (TLD) |
|
Routes of administration | By mouth |
| ATC code | |
Dolutegravir/lamivudine/tenofovir (DTG/3TC/TDF) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. [1] It is a combination of dolutegravir, lamivudine, and tenofovir disoproxil. [1] As of 2019 [update], it is listed by the World Health Organization (WHO) as the first line treatment for adults, with tenofovir/lamivudine/efavirenz as an alternative. [2] It is taken by mouth. [3]
Side effects may include trouble sleeping, weight gain, and rash. [2] [3] While there are concerns that use during pregnancy results in a 0.2% increased risk of neural tube defects in the baby, this does not rule out its use. [2] Use remains recommended after the first trimester. [2] Use is not recommended in those with kidney problems. [3] The combination is a type of antiretroviral therapy. [2]
It is on the World Health Organization's List of Essential Medicines. [4] In some countries it is available as a generic medication. [5] It is tentatively approved in the United States as of 2019, full approval is pending expiration of the US patents on dolutegravir (Tivicay) and tenofovir disoproxil (Viread). [6] [7]
Medical uses
As of 2019, it is listed by the World Health Organization (WHO) as the first-line treatment for adults with HIV/AIDS, with tenofovir/lamivudine/efavirenz as an alternative. [2] It may be used in people with both HIV and tuberculosis, however if the person is on rifampicin a larger dose of dolutegravir is needed. [2]
Side effects
Side effects may include trouble sleeping and weight gain. [2] While there are concerns that use during pregnancy results in a 0.2% increased risk of neural tube defects in the baby, this does not rule out its use. [2] Use remains recommended after the first trimester. [2] It should not be used with dofetilide. [3]
Society and culture
Economics
In the developing world it costs about US$75 per year. [8] It is considered more cost effective than tenofovir/lamivudine/efavirenz as of 2019. [2]
References
- ^ a b "Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD)" (PDF). World Health Organization (WHO). Retrieved 15 November 2019.
- ^ a b c d e f g h i j k World Health Organization (2019). "Policy brief: update of recommendations on first- and second-line antiretroviral regimens" (Document). World Health Organization. hdl: 10665/325892. WHO/CDS/HIV/19.15; License: CC BY-NC-SA 3.0 IGO.
- ^ a b c d "WHO-PQ Recommended summary of product characteristics" (PDF). July 2019. Archived from the original (PDF) on November 16, 2019. Retrieved 16 November 2019.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ "TDF/3TC/DTG" (PDF). Retrieved 16 November 2019.
- ^ "NDA 209618 Tentative Approval" (PDF). U.S. Food and Drug Administration (FDA). 25 March 2019. Retrieved 16 November 2019.
- ^ "NDA 210796 Tentative Approval" (PDF). U.S. Food and Drug Administration (FDA). 18 August 2017.
- ^ Vitoria M, Hill A, Ford N, Doherty M, Clayden P, Venter F, et al. (July 2018). "The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?". AIDS. 32 (12): 1551–1561. doi: 10.1097/QAD.0000000000001845. PMID 29746295. S2CID 13674631.
External links
- "Dolutegravir". Drug Information Portal. U.S. National Library of Medicine.
- "Lamivudine". Drug Information Portal. U.S. National Library of Medicine.
- "Tenofovir disoproxil". Drug Information Portal. U.S. National Library of Medicine.
- "Tenofovir disoproxil fumarate". Drug Information Portal. U.S. National Library of Medicine.
| Combination of | |
|---|---|
| Dolutegravir | Integrase strand transfer inhibitor |
| Lamivudine | Nucleoside reverse transcriptase inhibitor |
| Tenofovir disoproxil | Nucleoside reverse transcriptase inhibitor |
| Clinical data | |
| Other names | Tenofovir/lamivudine/dolutegravir (TLD) |
|
Routes of administration | By mouth |
| ATC code | |
Dolutegravir/lamivudine/tenofovir (DTG/3TC/TDF) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. [1] It is a combination of dolutegravir, lamivudine, and tenofovir disoproxil. [1] As of 2019 [update], it is listed by the World Health Organization (WHO) as the first line treatment for adults, with tenofovir/lamivudine/efavirenz as an alternative. [2] It is taken by mouth. [3]
Side effects may include trouble sleeping, weight gain, and rash. [2] [3] While there are concerns that use during pregnancy results in a 0.2% increased risk of neural tube defects in the baby, this does not rule out its use. [2] Use remains recommended after the first trimester. [2] Use is not recommended in those with kidney problems. [3] The combination is a type of antiretroviral therapy. [2]
It is on the World Health Organization's List of Essential Medicines. [4] In some countries it is available as a generic medication. [5] It is tentatively approved in the United States as of 2019, full approval is pending expiration of the US patents on dolutegravir (Tivicay) and tenofovir disoproxil (Viread). [6] [7]
Medical uses
As of 2019, it is listed by the World Health Organization (WHO) as the first-line treatment for adults with HIV/AIDS, with tenofovir/lamivudine/efavirenz as an alternative. [2] It may be used in people with both HIV and tuberculosis, however if the person is on rifampicin a larger dose of dolutegravir is needed. [2]
Side effects
Side effects may include trouble sleeping and weight gain. [2] While there are concerns that use during pregnancy results in a 0.2% increased risk of neural tube defects in the baby, this does not rule out its use. [2] Use remains recommended after the first trimester. [2] It should not be used with dofetilide. [3]
Society and culture
Economics
In the developing world it costs about US$75 per year. [8] It is considered more cost effective than tenofovir/lamivudine/efavirenz as of 2019. [2]
References
- ^ a b "Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD)" (PDF). World Health Organization (WHO). Retrieved 15 November 2019.
- ^ a b c d e f g h i j k World Health Organization (2019). "Policy brief: update of recommendations on first- and second-line antiretroviral regimens" (Document). World Health Organization. hdl: 10665/325892. WHO/CDS/HIV/19.15; License: CC BY-NC-SA 3.0 IGO.
- ^ a b c d "WHO-PQ Recommended summary of product characteristics" (PDF). July 2019. Archived from the original (PDF) on November 16, 2019. Retrieved 16 November 2019.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ "TDF/3TC/DTG" (PDF). Retrieved 16 November 2019.
- ^ "NDA 209618 Tentative Approval" (PDF). U.S. Food and Drug Administration (FDA). 25 March 2019. Retrieved 16 November 2019.
- ^ "NDA 210796 Tentative Approval" (PDF). U.S. Food and Drug Administration (FDA). 18 August 2017.
- ^ Vitoria M, Hill A, Ford N, Doherty M, Clayden P, Venter F, et al. (July 2018). "The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?". AIDS. 32 (12): 1551–1561. doi: 10.1097/QAD.0000000000001845. PMID 29746295. S2CID 13674631.
External links
- "Dolutegravir". Drug Information Portal. U.S. National Library of Medicine.
- "Lamivudine". Drug Information Portal. U.S. National Library of Medicine.
- "Tenofovir disoproxil". Drug Information Portal. U.S. National Library of Medicine.
- "Tenofovir disoproxil fumarate". Drug Information Portal. U.S. National Library of Medicine.